GlassScriptPhysician profile
Robert Joseph Obrien
NPI 1568566420
$7,828.90
in general payments reported to CMS, 2019-2025
28 companies · $739 in 2025
The $739 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $760 · 2020: $830 · 2021: $1,315 · 2022: $1,541 · 2023: $1,335 · 2024: $1,308 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,284 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,283.63 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,285.74 | 2019-2024 | |
| Amgen INC. | $1,260.32 | 2019-2025 | Otezla, Otezla, Enbrel |
| Janssen Biotech, INC. | $1,158.94 | 2019-2025 | Tremfya, Simponi, Stelara |
| Genzyme Corporation | $1,135.64 | 2019-2025 | |
| Lilly USA, LLC | $541.81 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $355.05 | 2022-2025 | Sotyktu |
| Abbvie INC. | $348.33 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $308.08 | 2020-2025 | Libtayo |
| Leo Pharma INC. | $295.76 | 2021-2023 | Adbry |
| Arcutis Biotherapeutics, INC. | $223.93 | 2023-2024 | Zoryve |
| Incyte Corporation | $143.67 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $138.68 | 2020-2025 | Ilumya |
| Ucb, INC. | $96.40 | 2020-2023 | Cimzia |
| Genentech USA, INC. | $96.22 | 2020-2022 | |
| Galderma Laboratories, L.P. | $92.34 | 2019-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $75.80 | 2019 | |
| Pfizer INC. | $41.50 | 2021-2022 | |
| Aclaris Therapeutics, INC. | $31.01 | 2019 | |
| Organogenesis INC. | $24.99 | 2023 | Puraply |
| Botanix Sb INC | $23.89 | 2025 | Sofdra |
| Dermira, INC. | $23.37 | 2020 | |
| Organon LLC | $23.19 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $21.45 | 2021 | |
| Dermavant Sciences, INC. | $18.34 | 2023 | Vtama |
| Biofrontera INC. | $16.79 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Fresenius Kabi USA, LLC | $16.22 | 2023 | Idacio |
| Almirall LLC | $15.96 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Obrien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.